Shenzhen Capital Group

Founded 1999


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 405
Average round size
The average size of a deal this fund participated in
Portfolio companies 369
Rounds per year 18.41
Lead investments 107
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 75
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Manufacturing
  • Health Care
  • Information Technology
  • Biotechnology
  • Software

In 1999 was created Shenzhen Capital Group, which is appeared as VC. The company was established in Asia in China. The main department of described VC is located in the Shenzhen.

The overall number of key employees were 4.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most popular portfolio startups of the fund, we may highlight Suning Finance, Royole Corporation, Desktop Metal. The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. We can highlight the next thriving fund investment areas, such as Internet, Manufacturing. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Shenzhen Capital Group, startups are often financed by IDG Capital, Sequoia Capital China, Matrix Partners China. The meaningful sponsors for the fund in investment in the same round are Qianhai Fund of Funds, Fortune Venture Capital, Vertex Ventures. In the next rounds fund is usually obtained by Sequoia Capital China, IDG Capital, SIG China (SIG Asia Investments).

The common things for fund are deals in the range of more than 100 millions dollars. The average startup value when the investment from Shenzhen Capital Group is more than 1 billion dollars. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 1 percentage points less often commits exit comparing to other organizations. This Shenzhen Capital Group works on 17 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 7-12 investment rounds annually. The increased amount of exits for fund were in 2010.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

OrbusNeich Medical

Health Care
$200M30 Aug 2021 New Territories, Hong Kong, China

Ionova Life Science

Health Care
$100M22 Aug 2021 Futian District, Guangdong Province, China

$46M10 Aug 2021 Futian District, Guangdong Province, China

Svolt Energy Technology Co.

Electric Vehicle
Energy Storage
$1B01 Aug 2021 Baoding City, Hebei, China


Supply Chain Management
$30M31 May 2021 Haidian District, Beijing, China

Clinical Trials
Innovation Management
$80M24 Mar 2021 Xuanwu District, Jiangsu, China

Changyang Tech

Enterprise Software
$30M17 Mar 2021 Dongcheng District, Beijing, China

$100M12 Mar 2021 Shanghai, China

Moore Threads

Artificial Intelligence
25 Feb 2021 Haidian District, Beijing, China
SVOLT Energy Closes RMB10.28 Billion Series B Financing

– SVOLT Energy Technology Co., Ltd. is a Beijing, China-based EV battery manufacturer.
– Company raised a total amount of RMB 10.28 billion ($US 1.58 billion) in Series B funding.
– The round was led by Bank of China Group Investment (BOCGI), Country Garden Venture Capital, Shenzhen Capital Group (SCGC), CCB Investment, IDG Capital, Sany, Xiaomi Corporation, Oceanpine Capital, CHINA RENAISSANCE among others.
– The Series B funds will be mainly used for R&D of new technologies and construction of new factories.

Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies

– Bioheng Biotech raised $80m in Series B financing.
– The round was led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with the participation of BlueRun Ventures and Shenzhen Capital Group Company.
– Proceeds will be used to advance R&D capabilities, process development and clinical trials.
– Bioheng is dedicated on developing novel cellular immunotherapy for cancer.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Shenzhen Capital Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: